COMMENTARY: Review: Human parathyroid hormone reduces fractures and increases bone mineral density in severe osteoporosis

Bauer, Douglas C.
November 2006
ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p71
Academic Journal
The article presents the author's comments on a study analyzing the effectiveness of human parathyroid hormone (hPTH) in patients with osteoporosis. According to the author, the study suggests that administration of hPTH increases bone mass and reduces vertebral fracture risk, but the fracture data have not been published and hPTH described in the study is not approved by U.S. Food and Drug Administration. He also asserts that the effects of hPTH on hip fracture are unknown.


Related Articles

  • Review: Human parathyroid hormone reduces fractures and increases bone mineral density in severe osteoporosis.  // ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p71 

    The article focuses on a study related to effectiveness of human parathyroid hormone (hPTH) in patients with severe osteoporosis. The study involved randomized controlled trials that compared hPTH with placebo or an active comparator in postmenopausal women or men with osteoporosis. The study...

  • Parathyroid hormone in osteoporosis. Purdie, David W.; Rees, Margaret // Journal of the British Menopause Society;2003, Vol. 9 Issue 4, p175 

    The article refers to a study conducted to analyze the role played by parathyroid hormone in the treatment of osteoporosis. Recently, teriparatide or the 1-34 genetically engineered fragment was licensed for prescription. The drug promotes substantial gains in bone mineral density. This, in...

  • Which Inhaler Combination is Best for COPD Treatment? Elliott, William T. // OB/GYN Clinical Alert;Apr2007, Vol. 23 Issue 12, p1 

    The article offers news briefs on issues related to medical care. Two clinical studies were conducted in England to examine the effect of inhaler combinations on outcomes in patients with chronic obstructive pulmonary disease (COPD). The U.S. Food and Drug Administration (FDA) has approved...

  • The Underuse of Therapy in the Secondary Prevention of Hip Fractures. Kamel, H.K.; Duthie, E.H. // Drugs & Aging;2002, Vol. 19 Issue 1, p1 

    There is strong evidence to indicate that individuals who sustain a hip fracture are at a greater risk of developing another. The management of such patients should include efforts to prevent future fractures, including prescribing medications that have been shown to lower hip fracture risk....

  • Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Kelechi E Nnoaham; Aileen Clarke // International Journal of Epidemiology;Feb2008, Vol. 37 Issue 1, p113 

    Objective To explore the association between low serum vitamin D and risk of active tuberculosis in humans. Design Systematic review and meta-analysis. Data sources Observational studies published between 1980 and July 2006 (identified through Medline) that examined the association between low...

  • Chronic Obstructive Pulmonary Disease Is Associated with Low Levels of Vitamin D. Pauline Persson, Louise Jeanette; Aanerud, Marianne; Hiemstra, Pieter Sicco; Hardie, Jon Andrew; Bakke, Per Sigvald; Lind Eagan, Tomas Mikal // PLoS ONE;Jun2012, Vol. 7 Issue 6, p1 

    Introduction: COPD patients may be at increased risk for vitamin D (25(OH)D) deficiency, but risk factors for deficiency among COPD patients have not been extensively reported. Methods: Serum 25(OH)D levels were measured by liquid chromatography double mass spectrometry in subjects aged 40- 76...

  • Alternate Treatment for Osteoporosis. Elliott, William T. // Clinical Cardiology Alert;Apr2007 Pharmacology Watch, p2 

    The article reports on a study which looks at recombinant human parathyroid hormone, a bone-forming agent, as an alternative treatment for osteoporosis. According to the article, antiresorptive agents prevent bone breakdown, however, they do not stimulate new bone production. After treatment,...

  • Teriparatide in Bisphosphonate-Resistant Osteoporosis: Microarchitectural Changes and Clinical Results After 6 and 18 months. Jobke, B.; Muche, B.; Burghardt, A.; Semler, J.; Link, T.; Majumdar, S. // Calcified Tissue International;Aug2011, Vol. 89 Issue 2, p130 

    number of osteoporotic patients under bisphosphonate treatment present persistent fragility fractures and bone loss despite good compliance. The objective of this 18-month prospective study was to investigate the effect of teriparatide [rhPTH(1-34)] in 25 female osteoporotics who were inadequate...

  • Forteo approved for new indication.  // Reactions Weekly;8/1/2009, Issue 1263, p2 

    The article announces the approval of the U.S. Food and Drug Administration (FDA) for the use of Eli Lilly and Company's teriparatide drug Forteo in treating osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women with a high fracture risk. Based on the clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics